Idera Pharmaceuticals Is A Clinical-stage Biopharmaceutical Company Developing Novel Nucleic Acid-based Therapies For The Treatment Of Certain Cancers And Rare Diseases.

Medline..ou can have it for a short time or for many years. The urea contains many blood vessels — the veins, arteries and capillaries — that carry blood to and from the eye. Uveitis disrupts vision by primarily causing problems with the lens, retina, optic nerve, and vitreous see diagram: Lens: Transparent tissue that allows light into the eye. The disease will cause symptoms, such as decreased vision, pain, light sensitivity, and increased floaters. Located between the sclera, the eye’s white outer coat, and the inner layer of the eye, called the retina, the urea consists of the iris, biliary body, and choroid: Iris: The coloured circle at the front of the eye. You may develop this condition if you have had a body-wide systemic infection or if you have an autoimmune disease. Other potential causes include fungus, bacteria, parasite, inflammatory disease affecting other parts of the body, or injury to the eye. For more severe cases, your ophthalmologist may recommend injections of corticosteroids into the eye, oral forms of corticosteroids or additional immunosuppressive medications. Read more about the side effects of corticosteroids .

Based on these studies, the company is also conducting studies to further the potential applications of 3GAs in targeting diseases caused by point mutations. Data from these studies is expected to be presented in the second half of 2016. http://dailydominiccoleman.pca-plus.com/2016/09/13/treatment-for-diabetic-retinopathy-is-often-delayed-until-it-starts-to-progress-to-pdp-or-when-dbe-occurs/This presentation is currently available on Ideras website at http://www.iderapharma.com/our-science/key-presentations-and-publications . Our in-depth understanding from our pioneering work in antisense technology along with our insights into the interaction of nucleic acids with Toll-like receptors has allowed us to design this very unique technology platform to fully realize the potential of antisense technology, stated Sudhir Agrawal, D. Phil., President of Research at Idera Pharmaceuticals. We are continuing to conduct preclinical studies with multiple 3GA candidates in house and with our collaborators, with a goal of advancing this technology to clinical development. Previously the company has announced the identification of NLRP3 (NOD-like receptor family, pyrin domain containing protein 3) and DUX4 (Double Homeobox 4) as initial gene targets to advance into IND-enabling activities, which will occur throughout 2016. Potential disease indications related to these targets include, but are not limited to, interstitial cystitis, lupus nephritis, uveitis and facioscapulohumeral muscular dystrophy (FSHD). The Company is currently conducting clinical, regulatory and commercial analysis activities and conducting IND-enabling studies with the plan to enter the clinic in 2017 for the first clinical development program. In addition to these activities, over the first half of 2016, Idera generated 3GA compounds for a series of additional gene targets. These will enable the Company to continue to expand its future pipeline opportunities for both internal development as well as partnerships in areas outside of Ideras focus. Additionally, Idera is party to a collaboration and license agreement with GSK to research, develop and commercialize compounds from its 3GA technology for the treatment of undisclosed, selected renal targets. About Ideras Third Generation Antisense Platform (3GA) Ideras proprietary third-generation antisense (3GA) platform technology is focused on silencing the mRNA associated with disease causing genes. Idera has designed 3GA oligonucleotides to overcome specific challenges associated with earlier generation antisense technologies and RNAi technologies. About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Ideras proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs.

For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/idera-pharmaceuticals-presents-novel-mechanism-110000559.html

This.ye temporarily stains the surface of the eye and can help to determine which layers of the eye are inflamed. The cause of non-infectious uveitis is unknown but there are some strong genetic factors that predispose disease onset including HLA-B27 20 21 and the PTPN22 genotype. 22 Diagnosis includes dilated funds examination to rule out posterior uveitis, which presents with white spots across the retina along with retinitis and vasculitis . Surgery to remove some of the vitreous in your eye vitrectomy may be necessary to manage the condition. Review provided by VeriMed Healthcare Network. In addition, your physician probably will ask you about your medical history, and will examine you. Uveitis can be associated with any of the following: Erasing the worldwide deficit of properly trained ocular immunologists through our fellowship program and continuing education of ophthalmologists around the world. Uncomplicated Systems For Glaucoma Explained | Dylan Young RockHow it affects you depend a lot on the cause and how quickly you get treated. Major histocompatibility antigen testing may be performed to investigate genetic susceptibility to uveitis. If you take steroids for a long time, you may have side effects, like cataracts, stomach ulcers, bone thinning called osteoporosis, diabetes, and weight gain. Each type is classified by where the inflammation occurs in the eye. Untreated or under-treated uveitis, or repeated episodes of inflammation within the eye, can lead to scarring and blinding consequences. Dr.

Leave a Reply

Your email address will not be published. Required fields are marked *